The OncoAlert ESMO 2025 Coverage
The OncoAlert Network had the great privilege of being on site at the European Society for Medical Oncology Congress 2025 in Berlin, Germany. It was an incredible year for science, with major breakthroughs presented and numerous high-impact publications released in journals such as The New England Journal of Medicine, and many more.
To enhance your ESMO experience, we’re excited to share a selection of exclusive videos from the congress. For a more comprehensive overview, we invite you to register for the COMPLETE #ESMO25 Newsletter by OncoAlert—your go-to resource for expert insights, highlights, and key takeaways from this year’s meeting.
Best,
The Network
To enhance your ESMO experience, we’re excited to share a selection of exclusive videos from the congress. For a more comprehensive overview, we invite you to register for the COMPLETE #ESMO25 Newsletter by OncoAlert—your go-to resource for expert insights, highlights, and key takeaways from this year’s meeting.
Best,
The Network
OncoAlert ESMO Daily Round Ups
|
In this OncoAlert Round Up from Day 2 of ESMO 2025, Dr. Gil Morgan spotlights DESTINY-Breast11, DESTINY-Breast05, evERA BC, RAMPART, and KEYNOTE-905/EV-303 — five practice-changing trials reshaping treatment in breast, renal, and bladder cancer through antibody–drug conjugates and novel immunotherapy combinations.
|
In this OncoAlert Round Up, Dr. Gil Morgan spotlights the Top 5 trials from Day 3 of ESMO 2025 — HARMONi-6, OptiTROP-Lung04, ASCENT-03, RC48-C016, and CAPItello-281/PSMAddition — showcasing major advances in lung, breast, urothelial, and prostate cancer through antibody–drug conjugates and biomarker-driven therapies reshaping modern oncology.
|
In this OncoAlert Round Up from Day 4 of ESMO 2025 in Berlin, Dr. Gil Morgan highlights IMvigor011, DYNAMIC-III, and FORTITUDE-101 — showcasing how ctDNA-guided and biomarker-driven strategies are transforming adjuvant and targeted therapy in bladder, colorectal, and gastric cancers.
|
Breast Cancer
|
Dr. Elisa Agostinetto from Institute Jules Bordet in Brussels Belgium, gives us her top picks in Breast Cancer presented in Berlin.
✅monarchE ✅NATALEE ✅Destiny Breast 05 ✅Destiny Breast 11 ✅ASCENT03 ✅TROPION Breast 02 Dr. Del Mastro: Presentati i dati degli studi ASCENT 03 e TROPION 02 che cambiano la prima linea di trattamento spostando in prima linea l’ADC (sacituzumab govitecan o datopotomab deruxtecan) nel carcinoma mammario triplo negativo avanzato #BreastCancer #tnbc
|
Dr. Del Mastro: Presentati a #ESMO25 i risultati aggiornati dello studio monarchE che dimostrano come abemaciclib nel trattamento adiuvante delle pazienti con carcinoma mammario ER+ ad alto rischio induce un vantaggio in sopravvivenza globale (Video in ITALIAN🇮🇹)
|
GU Cancer
|
Dr. Gilbert Morgan and the OncoAlert Faculty highlight the top three prostate cancer trials from ESMO 2025 — EMBARK, CAPItello-281, and PETRANHA — showcasing how precision medicine and novel combination strategies are redefining outcomes and setting new standards in prostate cancer care.
Dr. Enrique Grande, OncoAlert Faculty, presents the DISCUS trial (LBA 109) at ESMO 2025 — a phase II study comparing three Vs. six cycles of platinum-based chemotherapy before maintenance avelumab in adv. urothelial cancer, exploring optimal treatment duration & impact on patient outcomes
Join our Faculty Dr. Gillessen and Dr. Omlin from APCCC, live from Berlin as they break down the Radioligand Therapy session in prostate cancer from ESMO 2025. Discover the hottest updates, emerging strategies, and key debates that are set to spark discussions at #APCCC26 in Lugano.
El nuevo podcast de OncoAlert en nuestro idioma! Con nuestras colegas Dra. Natalia Gandur (Argentina) y Dra. Reginia Barragán (México). En este primer episodio, las doctoras Barragán-Carrillo y Gandur nos cuentan todos los avances de #ESMO25 en Cancer de vejiga
|
OncoAlert Faculty Dr. Brian Rini from the Vanderbilt-Ingram Cancer Center and Uromigos shares his Top Kidney Cancer (RCC) picks from ESMO 2025 in Berlin, breaking down the most impactful GU trials shaping the field — including RAMPART, O3A, and OPTIC.
OncoAlert Faculty Dr. Tom Powles presents the IMvigor011 trial at ESMO 2025, with a concurrent NEJM publication, showing that ctDNA is a powerful predictive and prognostic tool after cystectomy in muscle-invasive bladder cancer, paving the way for truly personalized adjuvant therapy.
OncoAlert Faculty Dr. Brian Rini discusses the OPTIC RCC Trial from ESMO 2025 in Berlin, where Dr. Scott Haake presented how cabozantinib plus nivolumab performs in metastatic clear cell renal cell carcinoma (Kidney Cancer) using a novel RNAseq-based biomarker.
|
Lung Oncology
|
Dr. Hidehito Horinouchi breaks down the HARMONi-6 Trial from ESMO 2025, a Phase III study comparing ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in first-line treatment of advanced squamous non-small cell lung cancer. Discover how ivonescimab significantly improves progression-free survival across PD-L1 levels with a manageable safety profile.
|
堀之内秀人医師が、ESMO 2025で発表されたHARMONi-6試験を解説します。本試験は、進行扁平上皮非小細胞肺がんの一次治療において、イボネシマブ＋化学療法とティスレリズマブ＋化学療法を比較した第III相試験です。イボネシマブがPD-L1レベルに関わらず無増悪生存期間を有意に改善し、管理可能な安全性プロファイルを示すことが明らかになりました。
|
GI Oncology
|
Dr. Nicholas Hornstein from the Northwell Health shares his Top GI Oncology picks from ESMO 2025 in Berlin, breaking down the most impactful GI trials shaping the field — NICHE2 and STELLAR 303 .
|
CLICK HERE FOR THE COMPLETE NEWSLETTER
